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Apoptotic cysteine–aspartate proteases (caspases) are essential for the progression and execution of apoptosis, and detection
of caspase fragmentation or activity is often used as markers of apoptosis. Cisplatin (cis-diamminedichloroplatinum (II)) is a
chemotherapeutic drug that is clinically used for the treatment of solid tumours. We compared a cisplatin-resistant pleural
malignant mesothelioma cell line (P31res1.2) with its parental cell line (P31) regarding the consequences of in vitro acquired
cisplatin-resistance on basal and cisplatin-induced (equitoxic and equiapoptotic cisplatin concentrations) caspase-3, -8 and -9
fragmentation and proteolytic activity. Acquisition of cisplatin-resistance resulted in basal fragmentation of caspase-8 and -9
without a concomitant increase in proteolytic activity, and there was an increased basal caspase-3/7 activity.Similarly, cisplatin-
resistant non-small-cell lung cancer cells, H1299res, had increased caspase-3 and -9 content compared with the parental H1299
cells. In P31 cells, cisplatin exposure resulted in caspase-9-mediated caspase-3/7 activation, but in P31res1.2 cells the cisplatin-
induced caspase-3/7 activation occurred before caspase-8 or -9 activation. We therefore concluded that in vitro acquisition of
cisplatin-resistance rendered P31res1.2 cells resistant to caspase-8 and caspase-9 fragments and that cisplatin-induced,
initiator-caspase independent caspase-3/7 activation was necessary to overcome this resistance. Finally, the results
demonstrated that detection of cleaved caspase fragments alone might be insufﬁcient as a marker of caspase activity and
ensuing apoptosis induction.
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Cysteinyl aspartate proteinases (caspases) are a large
protein family that includes proteins with important roles in
cell death pathways, including apoptosis.
1,2 There are three
major pathways of cell death in which caspases are activated;
the receptor-mediated pathway with initiator caspase-8, the
mitochondrial pathway with initiator caspase-9 and the
cytotoxic lymphocyte-initiated granzyme B pathway.
2 Gran-
zyme B is a protease that can cleave caspase-3 and -7 and
cleave Bid with subsequent activation of the mitochondrial
pathway.
2Intheothertwopathways,appropriatestimuliresult
in auto-activation of the initiator caspases in large multiprotein
complexes with subsequent processing of effector caspases,
including caspase-3 and -7, as well as other caspases and
effector proteins.
1,2 All caspases are expressed as inactive
precursors, pro-caspases. Activation is usually initiated
through proteolytic processing of the pro-caspase and
formation of a heterodimer that subsequently is dimerized to
formactiveheterotetramers.
1,2Activatedcaspase-3,-7and-9
are inhibited by the cytosolic X-linked inhibitor of apoptosis
(XIAP), probably the only bona ﬁde caspase inhibitor of the
IAP protein family.
3 The XIAP domains BIR1 and BIR2 bind to
the executor caspases and BIR3 binds to the initiator
caspase.
3,4 The XIAP-caspase interaction is counteracted
by proteins released from the mitochondria during activation
of the intrinsic pathway, for example, high-temperature
requirement protein (HtrA2).
5 Other IAPs include cIAP-1,
cIAP-2 and survivin, but the role of these proteins in caspase
inhibition is not as clear as that of XIAP.
3 Caspase-8 activity is
under the control of FLICE-inhibitory protein isoforms; FLICE-
inhibitory proteinS prevents the cleavage of caspase-8
between the p20 and p10 subunit, FLICE-inhibitory proteinL
inhibits the ﬁnal cleavage between the prodomain and the p20
subunit of the p43/41 intermediate.
6
It is recommended that detection of caspase fragments and
caspase proteolytic activity is performed simultaneously, to
reduce the risk of false negative results.
7,8 In addition to
immunoblotting detection of caspases and their endogenous
substrates,forexample,PARPcleavage forcaspase-3and-7
activity
9 or Bid cleavage for caspase-8 activity,
10 synthetic
substrates can be used in colorimetric or ﬂuorogenic assays
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11 Caspase-3 activity is often
used as a deﬁnite marker for apoptosis; however, there is as
yet no clear, accepted point-of-no-return for cell death
signalling pathways.
11 It is, therefore, important to determine
that caspase activation is followed by the demise of the cells,
for example, by determining that the cells have lost plasma
membrane integrity or undergone complete fragmentation
into discrete bodies.
11 The ﬂuorescein diacetate cytotoxicity
test is a method that determines plasma membrane integrity
and cellular viability.
12 The ﬂuorescein diacetate cytotoxicity
test performed in parallel with the detection of oligonucleoso-
mal DNA fragmentation using, for example, terminal deox-
ynucleotidyl transferase-mediated dUT nick-end labelling
assay can be used as an end-point assay for cellular
apoptosis.
13
Cisplatin (cis-diamminedichloroplatinum (II)) is a chemo-
therapeutic drug used for the treatment of solid tumours, such
as malignant mesothelioma and ovarian carcinoma.
14 The
use of cisplatin is limited by severe toxic side-effects, such as
nephrotoxicity and neurotoxicity, as well as by intrinsic or
acquired tumour resistance.
15 It is currently considered that
the main mechanisms of cisplatin resistance are decreased
accumulation of cisplatin in resistant cells; increased intra-
cellular trapping of cisplatin and increased repair of DNA
damage or increased tolerance of DNA damage.
16 Despite
this, a plethora of additional resistance mechanisms have
been described, including changes in the apoptosis signalling
pathways, such as decreased caspase-3 activation
17–19 and
failed activation of caspase-9.
18,20 To what extent these
changes are associated with any of the main mechanisms of
cisplatin-resistance mentioned above is not known. However,
in a cell model of acquired cisplatin resistance in malignant
pleural mesothelioma cells we have previously shown that
P31res1.2 cells have reduced NKCC1 activity and disrupted
K
þ-regulation.
13 It cannot be excluded that these changes
may affect caspase activity, as well as, for example,
accumulation and intra-cellular trapping of cisplatin. Further-
more, both caspase-3 and caspase-7 can cleave DNA
fragmentation factor 45/inhibitor of caspase-activated DNase
(DFF45/ICAD) and release active DNA fragmentation factor
40/caspase-activated DNase nuclease (DFF40/CAD), which
formshomo-oligomersandgeneratesdouble-strandbreaksin
DNA.
21Thus,changesincaspase-3and-7activation,andthe
cellular response to this activation, can be of signiﬁcance
when investigating cisplatin resistance mechanisms.
Previously, we have shown that acquisition of cisplatin-
resistance resulted in a higher basal caspase-3/7 activity, an
earlier cisplatin-induced increase in caspase-3/7 activity, but
no signiﬁcant changes in basal levels of nuclear DNA
fragmentation.
13 We have, therefore, determined the effect
of acquired cisplatin-resistance on caspase-3, -8 and -9
fragmentation and proteolytic activity in a human malignant
mesothelioma cell line of pleural origin, P31 and its cisplatin-
resistant sub-line P31res1.2.
13,22 The P31res1.2 cells are
about four times more resistant to cisplatin than the P31 cells,
with the equitoxic and equiapoptotic cisplatin concentrations
being 40mg/l and 10mg/l, respectively.
13 For comparison we
also investigated caspase expression and fragmentation
under control conditions in a cisplatin-resistant non-small-cell
lung cancer cell line H1299res and its parental cell line,
H1299. These cell lines have a similar difference in cisplatin
sensitivity as the P31 and P31res1.2 cells.
23 By using time-
resolved experiments, we show that this small change in
cisplatin-resistance resulted in increased fragmentation of
caspase-8 and -9, without a concomitant increase in activity.
The increased fragmentation appeared to be a consequence
of an increased caspase-3/7 activity observed in the
P31res1.2 cells.
Results
Acquisition of cisplatin-resistance increased basal
caspase-3/7 proteolytic activity but not caspase-3
fragmentation. We have previously shown that P31res1.2
cells are four-fold more resistant to cisplatin than their
parental P31 cells, with the equitoxic and equiapoptotic
cisplatin concentrations being 40mg/l and 10mg/l,
respectively.
13 In this study, we analyzed the cell lines in a
time-resolved manner by preparing cell lysates after 30min,
2h, 6h and 24h of cisplatin exposure (Figure 1). A caspase-
3/7 proteolytic activity assay using the ﬂuorescent substrate
DEVD-AFC (Figure 1a) conﬁrmed our previous ﬁnding of
increased basal caspase-3/7 activity in P31res1.2 cells.
13
This was further veriﬁed by the increase in PARP fragments
under control conditions in the P31res1.2 cells (Figure 1b). In
a Western blot screening of DFF45/DFF35 content in P31
and P31res1.2 cells, no changes were identiﬁed under
control conditions (data not shown). In addition, it was not
possible to detect any caspase-3 fragments under control
conditions in either cell line using western blotting
(Figure 1c), despite the use of antibodies from two different
companies (not shown). These antibodies could detect
caspase-3 fragments, as shown by the positive bands
detected after 24h of cisplatin exposure in both cell lines
(Figure 1c). By using a proteome proﬁler array, both pro-
caspase-3 protein and cleaved caspase-3 protein was
detected under control conditions in P31 and P31res1.2
cells (Figure 1d). The P31res1.2 cells had an increased
content pro-caspase-3 protein and, in contrast to the activity
assay results, a decreased content of cleaved caspase-3
protein. We therefore used western blot to screen the P31
and P31res1.2 cells for caspase-7 fragmentation, as
caspase-7 may substitute for caspase-3. However, both the
full-length caspase-7 and the cleaved fragments of
caspase-7 were reduced in P31res1.2 cells (data not
shown). A 6-h exposure to cisplatin was sufﬁcient to
increase the caspase-3/7 proteolytic activity in P31res1.2
cells (Figure 1a), but no change was seen in P31 cells. After
24h of cisplatin exposure, both caspase-3/7 proteolytic
activity and PARP fragmentation were similar in both cell
lines. We therefore concluded that acquisition of cisplatin-
resistance increased the basal effector caspase activity, but
did not change the ﬁnal response of the effector caspases-3
and -7 to cisplatin exposure. The P31res1.2 cells appeared
to be resistant to this increased basal activation, but not to
the cisplatin-induced activation, of caspase-3/7.
To determine whether the basal changes in effector
caspase contents were consistent ﬁndings after in vitro
acquisition of cisplatin resistance, we used western blotting
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Cell Death and Diseaseto screen the H1299 and H1299res cells for caspase-3,
caspase-7 and DFF45/DFF35 contents under control condi-
tions (Figure 1e). As in the P31res1.2 cells, full-length
caspase-3 protein was increased in H1299res cells, but it
was again not possible to detect any caspase-3 fragments by
western blotting. In contrast to the P31res1.2 cells (data not
shown), the H1299res cells had increased content of DFF45/
DFF35, as well as increased caspase-7 and caspase-7
fragmentation (Figure 1e). Thus, similar to the P31res1.2
cells, the H1299res cells appear to have increased basal
expression of effector caspase-3 subsequent to the in vitro
acquired cisplatin-resistance. However, the H1299res cells
also had increased basal expression and fragmentation of
caspase-7 that was not found in the P31res1.2 cells.
Acquisition of cisplatin-resistance increased caspase-8
and -9 fragmentation but not proteolytic activity. The
fragmentation and proteolytic activity of caspase-8 and -9
was examined in the same manner as for caspase-3. For
measuring proteolytic activity, the ﬂuorescent substrate
IETD-AFC was used as caspase-8 substrate, and LEHD-
AFC was used as caspase-9 substrate. Both caspase-8
and -9 fragmentations were increased in the P31res1.2 cells
under control conditions (Figure 2a). In particular, the 43
kDa-fragment of caspase-8 and the 35 and 37 kDa-
fragments of caspase-9 were increased. Despite the
increased basal fragmentation of caspase-8 and -9 there
was no increase of basal caspase-8 or -9 proteolytic activities
in P31res1.2 cells compared with P31 cells (Figure 2b).
Caspase-8 activity was also investigated by western blotting
of Bid and its truncated form tBid,
10 but there was never any
tBid detected in any of the samples (data not shown). A 6-h
cisplatin exposure increased only caspase-9 fragmentation in
the P31res1.2 cells (Figure 2a), but had no effect on the
proteolytic activity (Figure 2b). It was only after 24h of
cisplatin-exposure that caspase-8 and -9 proteolytic activities
were signiﬁcantly increased in both cell lines. At this time-
point, the amount of caspase-8 and -9 fragments was similar
in both cell lines, consistent with the similar levels of
proteolytic activity. It is notable that the p18 fragment of
caspase-8 was barely detectable, and the caspase-8 activity
was also lowest of the activities investigated. This suggested
to us that the major initiator caspase in both P31 and
P31res1.2 cells was caspase-9, and that the P31res1.2 cell
line had an increased inhibition of, or was resistant to,
fragmented caspase-9.
To determine whether the basal changes in activator
caspase contents were consistent ﬁndings after in vitro
acquisition of cisplatin resistance, we used western blotting
to screen the H1299 and H1299res cells for caspase-8 (not
shown) and caspase-9 contents (Figure 2c) under control
conditions. In contrast to the P31 and P31res1.2 cells
(Figure 2a), no fragments of caspase-8 were identiﬁed in the
H1299 or H1299res cells (not shown). However, as in the
P31res1.2 cells (Figure 2a),the H1299res cellshad increased
caspase-9 content and increased fragmentation of caspase-9,
compared with the parental H1299 cells (Figure 2c). Thus, the
effect of in vitro acquired cisplatin-resistance on activator
caspase-9 contents and fragmentation appear to be consis-
tent in different cell lines.
Acquisition of cisplatin-resistance increased cIAP-1,
cIAP-2, survivin and XIAP, as well as XIAP
fragmentation. We investigated the expression levels of
four inhibitor-of-apoptosis proteins, cIAP-1, cIAP-2, survivin
and XIAP in a Proteome proﬁler array. The expression levels
of cIAP-2, survivin and XIAP were increased in P31res1.2
cells (Figure 3a). We further investigated the possible role of
XIAP inhibition of caspase-9 activity by determining the
Figure 1 Effector caspase-3/7 activity and caspase-3 fragmentation in
malignant pleural mesothelioma cells (P31) and a sub-line with in vitro acquired
cisplatin-resistance(P31res1.2)determinedinabsenceandpresenceofequitoxicand
equiapoptotic concentrations of cisplatin, after exposure times as indicated.
(a) Caspase-3/7 activity determined in a ﬂuorometric assay using a ﬂuorescent-
tagged substrate, DEVD-AFC. **Po0.01, compared with control. Data presented as
means±S.E.M. of three separate experiments. (b) Western blot of full-length and
cleaved PARP as an endogenous indicator of caspase-3/7 activity. The membranes
were stripped and reprobed for actin as a protein loading control. Image
representative of at least three separate experiments. (c) Activation of caspase-3
determined by western blotting to detect full-length and cleaved versions of caspase-
3. The membranes were stripped and reprobed for actin as a protein loading control.
Image representative of at least three separate experiments. (d)P 3 1a n dP 3 1 r e s 1 . 2
content of full-length caspase-3 and cleaved caspase-3 determined with a Proteome
proﬁler array for human apoptosis-related proteins. Data presented as mean-
s±S.E.M. of duplicate analysis. (e) Detection of caspase-3 and caspase-7 by
western blotting under control conditions in non-small cell lung cancer cells (H1299)
and a sub-line with in vitro acquired cisplatin-resistance (H1299res)
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Cell Death and Diseaseexpression and fragmentation of XIAP and through western
blotting. Cell lysates were prepared after 2, 6 and 24h of
cisplatin exposure (Figure 3b). Both cell lines expressed
similar contents of full-length XIAP under control conditions,
whereas there was increased XIAP fragmentation with
fragments of about 40–45kDa in the P31res1.2 cells.
There was fragmentation of XIAP also in the P31 cells, but
with much lower levels of protein. HtrA2 not only counteracts
the XIAP-caspase interaction
5 but is also reported to mediate
cleavage of the protein yielding fragments of 30–45kDa.
24
Both western blotting (Figure 3b) and Proteome proﬁler
detection (Figure 3a) of HtrA2 expression in whole-cell
lysates suggested an increase in expression in the
P31res1.2 cells, but western blotting did not show any
effect of cisplatin exposure. In contrast, a 24-h cisplatin
exposure reduced both the expression of full-length XIAP
and XIAP fragmentation in both cell lines (Figure 3b).
Discussion
This study shows that a small increase in acquired cisplatin-
resistance may have a large impact on apoptotic caspase
fragmentation and proteolytic activity. We showed that
extensive initiator caspase fragmentation, without a conco-
mitant increase in proteolytic activity, occurred in malignant
pleural mesothelioma cells with in vitro acquired cisplatin-
resistance maintained at control conditions. These cells also
had increased caspase-3/7 proteolytic activity, but no
evidence of caspase-3 fragmentation. Furthermore, cisplatin
exposure resulted ﬁrst in activation of caspase-3/7, then
caspase-9 and to a much lesser extent caspase-8.
We, therefore, concluded that the in vitro acquisition of
cisplatin-resistance rendered the P31res1.2 cells resistant to
caspase-8 and caspase-9 fragments and that cisplatin-
induced caspase-3/7 activation was necessary to overcome
this resistance.
The effects of in vitro acquisition of cisplatin-resistance on
basal caspase-3 and -9 contents and fragmentation were
similar in H1299res cells and P31res1.2 cells. The H1299res
cells are non-small cell lung cancer H1299 cells with in vitro
acquired cisplatin-resistance established in our laboratory.
23 In
contrast to the P31res1.2 cells, the H1299res cells had
increased caspase-7 content and fragmentation, indica-
ting that caspase-7 may be upregulated and substitute for
caspase-3 in these cells. Although additional studies are
necessary to fully characterize the H1299 and H1299res cells
regarding caspase activity, the results indicate that in vitro
acquisition of cisplatin-resistance results in similar changes in
basalcaspase-3andcaspase-9expressionandfragmentation.
Caspase-9 activation is dependent on the assembly of a
functional apoptosome,
1,2 which in turn is dependent on
decreased intracellular K
þ concentration.
25 The P31res1.2
cells have deregulated K
þ transport because of the abro-
gated NKCC1 activity.
13 This, and the cisplatin-induced
caspase-9 fragmentation that was detected before any
increase in caspase-9 activity, suggested that the apopto-
some assembly or activation was transiently blocked in the
P31res1.2 cells. Similar indications of apoptosome dysfunc-
tion have been described during cisplatin exposure in non-
small cell lung cancer cells.
26 Another possible mechanism is
inhibitionof caspase-9activitybythe bindingofXIAP.
3,4 Inthe
P31res1.2 cells, there was increased fragmentation of XIAP,
Figure 2 Initiator caspase-8 and -9 fragmentation and activity in malignant pleural mesothelioma cells (P31) and a sub-line with in vitro acquired cisplatin-resistance
(P31res1.2),determinedinabsenceandpresenceofequitoxicandequiapoptoticconcentrationsofcisplatin,afterexposuretimesasindicated.(a)Westernblotsofcaspase-8
and -9 full-length proteins and cleaved fragments. The membranes were stripped and reprobed for actin as a protein loading control. Image representative of at least three
separate experiments. (b) Caspase-8 and -9 activities determined in a ﬂuorometric assay using ﬂuorescent-tagged substrates, IETD-AFC for caspase-8 and LEHD-AFC for
caspase-9.Basalactivitywasdeterminedincontrolcellsmaintainedwithoutcisplatinandcisplatin-inducedactivitywasdeterminedincellsexposedtoequitoxicconcentrations
ofcisplatinasindicated.*Po0.05,**Po0.01,comparedtocontrol.Datapresentedasmeans±S.E.M.ofthreeseparateexperiments.(c)Detectionof caspase-9bywestern
blotting under control conditions in non-small cell lung cancer cells (H1299) and a sub-line with in vitro acquired cisplatin-resistance (H1299res)
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Cell Death and Diseasebut it is not clear whether these fragments retain the caspase-9
or caspase-3-inhibiting function of XIAP. A third suggested
mechanism for inhibition of caspase-9 activation is phosphory-
lationatThr125by,forexample,extracellularsignal-regulated
kinase 1 and 2 (ERK1/2).
27 Although a more detailed
investigation is warranted, the involvement of extracellular
signal-regulated kinase1/2 is less likely as P31res1.2
cells have about half the amount of phosphorylated
extracellular signal-regulated kinase1 and extracellular
signal-regulated kinase2 present in P31 cells.
13
Caspase-8 activation occurs in a receptor-associated,
death-inducing signalling complex that is under the control
of FLICE-inhibitory protein.
6 In addition, cleaved caspase-8 is
reported to be inhibited by Src-mediated phosphorylation,
which inhibits processing of caspase-8 fragments to generate
the p18 subunit that is the most active subunit.
28 Although it
remains to be veriﬁed, our results are consistent with such an
inhibition of caspase-8 activity, as only a very small amount of
the p18 subunit was detectable after 24 of cisplatin exposure
inbothcelllines,concomitantwithaslightincreaseincaspase
8 proteolytic activity.
The increased basal fragmentation of caspase-8 and -9 in
the P31res1.2 cells was secondary to the increased basal
caspase-3/7 activity. As there was no increased caspase-3
fragmentation in the P31res1.2 cells, it is possible that the
in vitro acquisition of cisplatin-resistance had resulted in a
chronic increaseincaspase-7translation.
29 Regardlessofthe
mechanism, our results conﬁrm that there is a threshold of
caspase-3/7 activity that must be exceeded for apoptosis to
progress, similar to that shown by Rehm et al., 2006.
30 A
cisplatin-induced release of active caspase-3/7 from
XIAP
1,2,30 seemed unlikely as there were no caspase-3/7
fragments detected before 24h of cisplatin exposure. How-
ever, the decreased XIAP expression after 24h of cisplatin
expressionmayhavecontributedtotheincreaseincaspase-3
and -9 activities, which in turn can stimulate a positive feed-
back loop with caspase-3 and -9 cleaving and activating one
another.
31 Caspase-3 and caspase-7 have very similar
proteolytic activity, but there are differences in efﬁciency
toward their substrates.
32 They both have similar efﬁciency in
cleavage of, for example, DEVD-AFC and PARP, whereas
caspase-3ismoreefﬁcientintheproteolysisofcaspase-9and
XIAP.
32 Caspase-3-mediated fragmentation of caspase-9
occurs at Asp330 and results in a 37-kDa fragment,
31 the
most abundant fragment in the P31res1.2 cells. In contrast,
the XIAPfragmentsweretoo largetobethe result ofcaspase-
3-mediated cleavage.
4 Thus, another mechanism for the
XIAP cleavage seemed more plausible, for example, HtrA2
protease activity, which can result in XIAP fragments of
30–45kDa,
24 that is, similar to those found in this study.
Whether there is a difference in efﬁciency between caspase-3
and -7 regarding cleavage of caspase-8 is not known.
However, caspase-3-mediated fragmentation of caspase-8
is reported to result in 41 and 43kDa fragments,
33 such as
those found in this study.
It was notable that three of the four investigated IAP:s,
cIAP-2, survivin and XIAP, were increased in the P31res1.2
cells under control conditions. Although the role of cIAP-2 and
survivin in caspase inhibition is not as clear as that of XIAP,
3 it
cannot be excluded that they are relevant in the frame of
cisplatin-resistance, especially considering the lack of corre-
lation between caspase fragmentation and caspase activity
shown in this study. This lack of correlation also emphasizes
the importance of combining detection of pro-caspase
cleavage and caspase activity when evaluating induced
apoptosis by caspase activation.
7,8 Previously, the main
concern has been the risk of false negative results as a
consequence of using only caspase fragmentation as marker
of activity, based on the observation that, for example,,
caspase-9 can be activated without proteolytic processing.
34
The results presented here show that analysis of caspase
fragmentation also can give false positive results.
To conclude, malignant pleural mesothelioma cells with
in vitro acquired cisplatin resistance were resistant to initiator
caspase fragmentation with an increased basal caspase-3/7
activity and initiator-caspase independent cisplatin-induced
activation of caspase-3/7. The parental cell line, which was
less resistant to cisplatin, appeared to have caspase-9-
mediated, cisplatin-induced caspase-3 activity. Thus, acquisi-
tion of cisplatin-resistance may cause resistance to caspase
activation and activity, particularly through the caspase
9-mediated pathway. Finally, the lack of correlation between
caspase fragmentation and caspase activity showed that
detection of fragments alone is insufﬁcient as a marker of
caspase activity and therefore apoptosis induction.
Figure 3 Expression of inhibitor of apoptosis proteins and HtrA2 in in vitro
acquired cisplatin-resistance. (a) P31 and P31res1.2 content of c-IAP1, c-IAP2,
survivin, XIAP and HtrA2 determined with a Proteome proﬁler array for human
apoptosis-related proteins. Data presented as means±S.E.M. of duplicate
analysis. (b) Detection of the caspase-3 and -9 inhibitor XIAP and of the XIAP
inhibitor HtrA2XIAP in malignant pleural mesothelioma cells (P31) and a sub-line
with in vitro acquired cisplatin-resistance (P31res1.2), determined in absence and
presence of equitoxic and equiapoptotic concentrations of cisplatin, after exposure
times as indicated. Actin was used as protein loading control. Image representative
of three separate experiments
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Cell culture. A humanmalignantmesotheliomacellline of pleural origin(P31)
22
and its cisplatin-resistant sub-line (P31res1.2 with a 4  increased LD50)
13 was
used. Both cell lines were propagated at 371C in a humidiﬁed atmosphere
containing 5% CO2, grown as monolayer cultures in Eagle’s minimal essential
culturemediumwithEarl’ssaltssupplementedwith10%fetalcalfserum,200mmol/l
L-glutamine, gentamicine and, in the case of the P31res1.2 cells, 1.2mg/l, cisplatin.
The cells were exposed to equitoxic and equiapoptotic concentrations of cisplatin,
10mg/l for P31 cells and 40mg/l for P31res1.2 cells for 0.5, 2, 6 or 24h and
thereafter analyzed regarding caspase fragmentation and proteolytic activity.
13
Western blotting. Western blotting was performed as described previously.
13
In brief, the cells were harvested by trypsination immediately after exposures, lyzed
in lysis buffer (50mmol/l Tris 7.5, 1% Triton X-100, 150mmol/l NaCl and 1mmol/l
NaF,1 complete proteaseinhibitorEDTA-free cocktailtabletto 50ml buffer, Roche,
Manheim, Germany) and stored at  801C until analysis. A BCA protein assay
reagent kit was used according to the manufacturers’ instruction (Pierce
Biotechnology, Rockford, IL, USA) to determine the total protein content of
lysates. Lysates from two separate experiments were loaded on the same gel. An
amount of 20 mg proteins per sample were separated with SDS-PAGE and
transferred to PVDF-membranes (Bio-Rad Laboratories, Hercules, CA, USA). After
incubation with appropriate primary and secondary antibodies, the protein bands
were visualized(ECL Advance Western BlottingDetection Kit, GE Healthcare, Little
Chalfont, UK) and quantiﬁed with the Chemidoc XRS system and Quantity One 1-D
Analysis software (Bio-Rad Laboratories). All membranes were stripped
17 and
probed with actin antibody (Millipore, Billerica, MA, USA) to use actin bands as
protein loading control. The primary antibodies used were against caspase-3
(Cell Signaling Technology, Boston, MA, USA), caspase-8 (Alexis Biochemicals,
Lausen, Switzerland), caspase-7, caspase-9, PARP, DFF45/35, Bid, HtrA2 and
XIAP (all Cell Signaling Technology).
Proteome proﬁler array. A Proteome proﬁler array for human apoptosis-
related proteins (R&D Systems, Minneapolis, MN, USA) was used for the parallel
determination of relative levels of caspase-3 (full-length and cleaved fragments),
HtrA2 and four inhibitors of apoptosis proteins (IAPs) in P31 and P31res1.2 cells.
Thearraywasusedaccordingtothemanufacturer’sinstructions.Brieﬂy,cellsplated
on 15-cm culture plates were grown to about 80% conﬂuence, washed with cold
phosphate-bufferedsalineandlyzedwiththekit-includedlysisbuffer.ABCAprotein
assay reagent kit was used according to the manufacturers’ instruction (Pierce
Biotechnology) to determine the total protein content of lysates. The array
membranes were incubated overnight with 300mg protein per membrane and
processed according to manufacturer’s instructions. The array spots were detected
(ECL Advance Western Blotting Detection Kit, GE Healthcare), visualized and
quantiﬁed with the Chemidoc XRS system and Quantity One 1-D Analysis software
(Bio-Rad Laboratories). For quantiﬁcation the spot volume was determined,
corrected for background and expressed as percent of positive control.
Caspase activity ﬂuorometric assay. To determine caspase activity,
ﬂuorometric caspase activity assays (R&D Systems) were used according to the
manufacturers’ instructions, as described previously.
13 In brief, the cells were lyzed
immediately at the end of exposures (kit-included lysis buffer) and the supernatant
was stored at  801C until analysis. A BCA protein assay reagent kit was used
according to the manufacturers’ instruction (Pierce Biotechnology) to determine the
total protein content of lysates. 100mg proteins were incubated with ﬂuorescent
substrate;DEVD-AFCforcaspase-3/7,IETD-AFCforcaspase-8andLEHD-AFCfor
caspase-9 and ﬂuorescence was determined in a LS55 Luminescence
spectrometer (PerkinElmer, Waltham, MA, USA). 400 and 505nm was used for
excitation and emission, respectively. The results were corrected for background
ﬂuorescence, and the data is presented as ﬂuorescence per 100mg total protein.
Chemicals. Culture medium (Eagle’s MEM with Earle’s salts) and L-glutamine
were from Gibco Ltd. Fetal calf serum was purchased from Biochrom KG (Berlin,
Germany), cisplatin (CAS 15663-27-1) was from Bristol-Myers Squibb (New York,
NY, USA). All other chemicals were of analytical grade.
Statistical analysis. All results are presented as means±S.E.M., and for
statistical analysis, the SPSS 12.0.1 for Windows program was used. When normal
distribution could be assumed, an independent Student’s t-test was used for effect
of exposure time and cell type. When normal distribution could not be assumed, the
Wilcoxon’s Signed Ranks test were used for effect of cisplatin concentration, and
the Mann–Whitney U-test for the effect of exposure time and cell type. P-values
from two-sided tests were used, and the level of signiﬁcance for rejecting the null
hypothesis of zero effect was taken to be p r 0.05.
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